Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Table 2 Survival times of patients with or without extramedullary manifestations in the entire patient cohort

Survival times	EM AML	Non-EM AML	Hazard ratio	Cox regression p-value
Event-free survival	7.1 [4.8–9.1]	8.4 [7.7–9.6]	1.17 [1.00–1.37]	0.056
Relapse-free survival	12.6 [9.3–13.4]	19.3 [16.3–23.7]	1.11 [0.90–1.36]	0.315
Overall survival	14.0 [10.6–18.4]	26.2 [22.4–32.6]	1.38 [1.16–1.63]	< 0.001

Survival times in months. Cox-proportional hazard models were used to obtain univariable hazard ratios. Brackets show 95%-confidence intervals. Statistically significant p-values are marked in bold

ISSN: 1756-8722